Earlier this year 23andMe and Genentech launched an online study of metastatic breast cancer to learn more about how genes might play a role in how a person responds to bevacizumab, also known as Avastin®. (Avastin® is not approved by the FDA for treatment of metastatic breast cancer.) Since women began to ...
Return to top
July 31, 2012